Vaccine by Novavax, produced by SK Bioscience

Signed a LOI for cooperation between the MOHW and the three companies, diversifying platforms for smooth supply and demand

The government has signed a letter of intent (LOI) for cooperation in domestic production and supply in order to smoothly supply the vaccine developed overseas for COVID-19.

 

The domestic supply chain is SK Bioscience, which has joined the production of AstraZeneca products.

 

The MOHW (Minister Park Neung Hoo) at SK Bioscience Research Institute (Pangyo, Seongnam) at 9 p.m.

 

on the 13th, together with Novavax (CEO Stanley C.

 

Erck) and SK Bioscience (CEO Ahn Jae-yong), COVID-19 being developed by US Novavax.

 

A letter of intent (LOI) was signed for cooperation in global production and domestic supply of vaccines.

 

Currently, about 160 COVID-19 vaccines are being developed worldwide, and these vaccine candidates are largely classified into ▲viral carriers ▲synthetic antigens ▲nucleic acids (DNA, mRNA) ▲inactivated types (platforms) according to the type of technology.

 

The vaccine being developed by Novavax is a synthetic antigen method, which is different from the virus carrier vaccine being developed by AstraZeneca, UK, which signed a LOI for cooperation in securing domestic vaccine supply for the first time in July.

 

As it aims to enter phase III clinical trials in October this year, it is evaluated that the development speed is the fastest among synthetic conjugated vaccines.

 

The MOHW said, "This agreement signifies that a domestic company has been recognized for the production capacity and technology level of vaccine supply from other platforms, and participates in the global production and supply chain.

 

It is of great significance in that it has prepared a channel for cooperation to secure vaccines from Novavax, which has a different vaccine platform following AstraZeneca in July.” At the signing ceremony, The MOHW (Minister Park Neung Hoo) said, "Following July, the signing of a LOI has been a very big achievement as it has been able to further increase the possibility of supplying vaccines to Korea by diversifying available vaccines in preparation for the uncertainty of the success of vaccine development.

 

The government supports domestic companies' own vaccine development until the end, while making great efforts to quickly secure excellent overseas vaccines with a fast development speed based on a two-track strategy."